Management of cardiogenic shock attributable to acute myocardial infarction in the reperfusion era

Journal of Intensive Care Medicine

Volumn 20, Issue 4, 2005, Pages 188-198

  Duvernoy, Claire S ^a   Bates, Eric R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angioplasty; Cardiogenic shock; Fibrinolysis; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; ANISTREPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; DOBUTAMINE; DOPAMINE; DUTEPLASE; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; HYPERTENSIVE AGENT; INOTROPIC AGENT; MILRINONE; MORPHINE SULFATE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYLEPHRINE; RETEPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; AORTA BALLOON; CARDIOGENIC SHOCK; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COUNTERPULSATION; DEEP VEIN THROMBOSIS; HEART REINFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION; REVASCULARIZATION; REVIEW; TACHYCARDIA; THROMBUS; VENTILATOR; ALGORITHM; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; METHODOLOGY; RESUSCITATION;

ALGORITHMS; HUMANS; INTRA-AORTIC BALLOON PUMPING; MYOCARDIAL REVASCULARIZATION; RESUSCITATION; SHOCK, CARDIOGENIC; THROMBOLYTIC THERAPY;

EID: 27744541386     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066605276802     Document Type: Review

References (65)

1. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457-464.
2. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med. 1991;325:1117-1122.
3. Bates ER, Moscucci M. Post-myocardial infarction cardiogenic shock. In: Brown DL, ed. Cardiac Intensive Care. Philadelphia, Pa: Saunders; 1998:215-227.
4. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction-Etiologies, management and outcome: a report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;36:1063-1070.
5. Hochman JS, Sleeper L, Webb J, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625-634.
6. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190-192.
7. Menon V, White H, LeJemtel T, et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1071-1076.
8. Jacobs AK, Sleeper LA, Forman R, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol. 2003;41:1273-1279.
9. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1004-1109.
10. Menon V, Webb JG, Hillis LD, et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1110-1116.
11. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1117-1122.
12. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol. 1995;26:668-674.
13. Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation. 1999;100:2067-2073.
14. Jacobs AK, French JK, Col J, et al. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1091-1096.
15. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med. 2000;108:374-380.
16. Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction. Angiographic findings from the SHOCK trial. J Am Coll Cardiol. 2003;42:1373-1379.
17. Hollenberg, SM. Clinical assessment and initial management of cardiogenic shock. In: S.M. Hollenberg, Bates ER, eds. Cardiogenic Shock. Armonk, NY: Futura; 2002:45-59.
18. Nishimura RA, Tajik AJ, Shub C, Miller FA Jr, Ilstrup DM, Harrison CE. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol. 1984;4:1080-1087.
19. Picard MH, Davidoff R, Sleeper L, et al. Echocardiographic predictors for survival and response to early revascularization in cardiogenic shock. Circulation. 2003;107:279-284.
20. Hudson MP, Ohman EM. Intra-aortic balloon counterpulsation for cardiogenic shock complicating acute myocardial infarction. In: Hollenberg SM, Bates ER, eds. Cardiogenic Shock. Armonk, NY: Futura; 2002:81-102.
21. Kern MJ, Aguirre F, Bach R, et al. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. Circulation. 1993;87:500-511.
22. Scheidt S, Wilner G, Mueller H, et al. Intra-aortic counterpulsation in cardiogenic shock: report of a cooperative clinical trial. N Engl J Med. 1973;288:979-984.
23. O'Rourke MF, Norris RM, Campbell TJ, et al. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol. 1989;47:815-820.
24. Anderson RD, Ohman EM, Holmes DR Jr, et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. J Am Coll Cardiol. 1997;30:708-715.
25. Kovach PJ, Rasak MA, Bates ER, Ohman EM, Stomel RJ. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol. 1997;29:1454-1458.
26. Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J. 2001;141:933-939.
27. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 200;36:1123-1129.
28. Ohman EM, Nannas J, Stomel RJ, et al. Thrombolysis and counterpulsation to improve cardiogenic shock survival (TACTICS): results of a prospective randomized trial (abstract). Circulation. 2000;102:II-600.
29. Ohman EM, George BS, White CJ, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. Circulation. 1994;90:792-799.
30. Ishihara M, Sato H, Tateishi H, et al. Intraaortic balloon pumping as adjunctive therapy to rescue coronary angioplasty after failed thrombolysis in anterior wall acute myocardial infarction. Am J Cardiol. 1995;76:73-75.
31. Stone GW, Marsalese D, Brodie BR, et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol. 1997;29:1459-1467.
32. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
33. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
34. Meinertz T, Kasper W, Schumacher M, et al. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol. 1988;62:347-351.
35. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
36. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
37. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
38. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
39. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
40. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol. 1992;19:885-891.
41. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993:329:673-682.
42. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346:329-336.
43. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol. 1991;18:1077-1084.
44. Becker RC. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J. 1993;125:919-929.
45. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;20:1626-1633.
46. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J. 1999;20:1030-1038.
47. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J. 2003;24:828-837.
48. Dauerman HL, Ryan TJ, Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol. 2003;15:380-384.
49. Antoniucci D, Valenti R, Migliorini A, et al. Comparison of impact of emergency percutaneous revascularization on outcome of patients = 75 to those < 75 years of age with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2003;91:1458-1460.
50. Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol. 1998;31:294-300.
51. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2002;89:132-136.
52. Yip H-K, Wu C-J, Chang H-W, et al. Comparison of impact of primary percutaneous transluminal coronary angioplasty and primary stenting on short-term mortality in patients with cardiogenic shock and evaluation of prognostic determinants. Am J Cardiol. 2001;87:1184-1188.
53. Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2002;89:126-131.
54. DiSesa V, Patel M, Hollenberg SM. Coronary artery bypass grafting for cardiogenic shock. In: Hollenberg SM, Bates ER, eds. Cardiogenic Shock. Armonk, NY: Futura; 2002:103-117.
55. Normal JC, Cooley DA, Igo SR, et al. Prognostic indices for survival during postcardiotomy intra-aortic balloon pumping. Methods of scoring and classification, with implications for left ventricular assist device utilization. J Thorac Cardiovasc Surg. 1977;74:709-720.
56. Vogel RA, Shawl F, Tommaso C, et al. Initial report of the National Registry of Elective Supported Angioplasty. J Am Coll Cardiol. 1990;15:23-29.
57. Bartlett RH, Roloff DM, Custer JR, Younger JG, Hirschl RB. Extracorporeal life support: the University of Michigan experience. JAMA. 2000;283:904-908.
58. Magliato KE, Kleishi T, Soukiasian HJ, et al. Biventricular support in patients with profound cardiogenic shock: a single center experience. ASAIO J. 2003;49:475-479.
59. Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. 2001;104:2917-2922.
60. Topol EJ, Neumann F-J, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886-1889.
61. Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol. 2002;90:353-357.
62. Hochman, JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998-3002.
63. Depre C, Vanoverschelde J-L, Goudemant J-F, et al. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation. 1995;92:1911-1918.
64. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101:1358-1361.
65. Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J. 2003;24:1287-1295.